Effects of anti-thymocyte serum (ATS) and anti-Thy 1, 2 monoclonal antibody on the spontaneously occurring diabetes in NOD mice were examined.
(Received 29 January 1986/Accepted 25 April 1986) Effects of anti-thymocyte serum (ATS) and anti-Thy 1, 2 monoclonal antibody on the spontaneously occurring diabetes in NOD mice were examined.
Spontaneous diabetes in female mice was markedly suppressed by intravenous injection of rabbit antimouse thymocyte serum diluted to 1:4 on three consecutive days during the time period from 70 to 100 days after birth; the cumulative incidence of overt diabetes upto 195 days of age was greatly reduced and the onset of diabetes was delayed.
Similar effect was observed with anti-Thy 1, 2 antibody treatment.
These findings suggest that T lymphocytes play a role in the production of spontaneous diabetes in this mouse strain.
Non-obese diabetes-prone (NOD) mouse is a novel inbred strain which develops spontaneous insulin-dependent diabetes mellitus. The features of the pathogenesis have been described elsewhere [3, 4] . This strain has been regarded as a good animal model for human Type I insulin-dependent diabetes, and therefore, the pathogenic mechanism is now being investigated from various standpoints. Attention has been particularly paid to the possibility that auto immunities to pancreatic islet cells of the humoral and/or cellular types might be involved in some stages in the development of overt diabetes.
To examine this possibility, we carried out a series of experiments to ascertain whether immunological treatment could affect the pathogenesis.
In the present study, on the analogy of the report that spontaneous diabetes in the BB rat is suppressed by multiple injections of anti-lymphocyte serum [2] we studied the suppressive effects of anti-thymocyte serum (ATS) and anti-Thy 1, 2 monoclonal antibody prepartion on spontaneous diabetes in NOD mice.
Female NOD mice aged 55-100 days were kept under specific pathogen-free conditions. Female DS/Shi mice (aged 60 days) were employed as the source of thymocytes for the determination of antibody activity of ATS. All the mice were given a commercial diet CA-1 (Japan Clea, Tokyo, JPN) and tap water ad libitum.
Rabbit antiserum to mouse thymocytes was purchased from Cappel Laboratories, Cockranville, PA, USA (Lot 11940). Antibodies to mouse tissue antigens other than those specific to thymocytes were removed by absorption with acetone powder of mouse liver (Cappel Laboratories, Lot 14769). In brief, 8 ml of ATS was mixed with 1 g acetone powder of mouse liver which had previously been washed three times with phosphate-buffered saline solution (pH 7.0). islets proceeds so slowly that only a few doses of these antibody preparations are sufficient to keep the autoimmunity at a reduced level for a long time.
Although hyperglycemia and elevated plasma glucose concentration have been reported to return to normal levels after treatment with anti-lymphocyte serum (ALS) in approximately 38,90 of diabetic BB rats [2] , ATS treatment after the onset of diabetes failed to exert such a curative effect in five out of six NOD mice. The discrepancy between the findings in the BB rat and the NOD mouse might be due to the difference in the frequency of the treatment (ALS was injected to the rats three times weekly for 30 days).
